GO:0034987 immunoglobulin receptor binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0034987 (immunoglobulin receptor binding) is a molecular function defined as binding to one or more specific sites on an immunoglobulin receptor molecule.
• The term is synonymous with Fc receptor binding and is central to how antibodies and immunoglobulin-like ligands engage cell-surface receptors.
• Immunoglobulin receptor binding underlies B-cell antigen receptor clustering, immune complex recognition, and mucosal immunoglobulin transport.
• Immunoglobulin-like domains are recurrent binding modules, as shown for the polymeric immunoglobulin receptor and for NGF binding to the Trk tyrosine kinase receptor.
• Pathogen and toxin interference with immunoglobulin receptor binding is a real biological phenomenon, exemplified by human milk components inhibiting Clostridium difficile toxin A-receptor binding.
• CRISPR knockout, point-mutation, knock-in, and overexpression models are the standard tools for dissecting immunoglobulin receptor binding in cells and animals.
Description
GO:0034987, immunoglobulin receptor binding, is a molecular function term in the Gene Ontology that describes the binding of a protein or ligand to one or more specific sites on an immunoglobulin receptor molecule. Immunoglobulin receptors are cell-surface or soluble proteins that recognize the constant or variable regions of immunoglobulins, and their engagement initiates signaling, transport, or clearance events. The term is widely used in immunology, virology, and cell biology because it captures the physical interaction step that precedes receptor activation or cargo internalization. The synonym Fc receptor binding reflects the historical focus on Fc receptors, but the term also covers interactions with polymeric immunoglobulin receptors and other immunoglobulin-like receptor systems. Understanding this function matters because it is the entry point for antibody-mediated effector functions, mucosal immunity, and pathogen-receptor interactions. Researchers studying GO:0034987 are typically interested in how immunoglobulin valency, receptor clustering, and domain architecture control downstream responses.
immunoglobulin receptor binding At A Glance
| GO ID | GO:0034987 |
|---|---|
| GO term | immunoglobulin receptor binding |
| Ontology | molecular_function |
| Synonym | Fc receptor binding |
| Definition | Binding to one or more specific sites on an immunoglobulin receptor molecule. |
| Major function | Mediates physical engagement of immunoglobulins or immunoglobulin-like ligands with their receptors, initiating signaling, transport, or clearance. |
| Representative receptors | Fc receptors, polymeric immunoglobulin receptor, and immunoglobulin-domain-containing receptors such as Trk. |
| Related biology | B-cell antigen receptor clustering, mucosal immunoglobulin transport, and pathogen-receptor interactions. |
| Research relevance | Target for antibody engineering, vaccine design, and studies of immune complex recognition. |
What Is GO:0034987?
In plain terms, GO:0034987 means the ability of a molecule to stick to a specific site on an immunoglobulin receptor. The QuickGO definition states that this is binding to one or more specific sites on an immunoglobulin receptor molecule. It is a molecular function, not a process or a location, and it is often used when annotating the direct physical contact between an immunoglobulin or immunoglobulin-like ligand and its receptor. The synonym Fc receptor binding is commonly used when the receptor is an Fc receptor, but the term is broader and includes polymeric immunoglobulin receptors and other immunoglobulin-domain-containing receptors.
Why Is immunoglobulin receptor binding Important in Cell Biology?
Immunoglobulin receptor binding is important because it is the molecular handshake that converts antibody recognition into cellular action. When an immunoglobulin binds its receptor, the interaction can trigger immune cell activation, receptor clustering, transcytosis, or pathogen neutralization. This function is also a point of vulnerability: pathogens and toxins can interfere with immunoglobulin-receptor interactions, as shown by human milk components that inhibit Clostridium difficile toxin A-receptor binding. Because the binding step is often the first committed event in an immune response, it is a prime target for therapeutic antibodies, receptor-blocking drugs, and diagnostic reagents.
• Defines the physical interaction that initiates antibody-mediated effector functions.
• Controls B-cell antigen receptor clustering and scale-dependent signaling.
• Enables mucosal immunity through polymeric immunoglobulin receptor transport.
• Provides a mechanism for pathogen-receptor engagement, as seen for picornaviruses.
• Can be modulated by host factors such as human milk components that block toxin-receptor binding.
• Involves immunoglobulin-like domains that are also used in growth factor receptor binding, e.g., NGF binding to Trk.
• Is a target for therapeutic antibody engineering and receptor-blocking strategies.
• Is relevant to lectin and immunoglobulin-domain receptor families such as I-type lectins.
• Can be studied with CRISPR models to separate binding from downstream signaling.
• Links basic receptor biochemistry to infectious disease and immunotherapy.
Molecular Mechanism of immunoglobulin receptor binding
Ligand recognition and receptor engagement
In simple terms: The immunoglobulin or immunoglobulin-like ligand first finds and docks onto a specific site on the receptor.
Immunoglobulin receptor binding begins with recognition of a specific site on the receptor by an immunoglobulin or immunoglobulin-like ligand. The interaction is typically mediated by immunoglobulin domains or immunoglobulin-like folds, as illustrated by the polymeric immunoglobulin receptor in largemouth bass and by the requirement of extracellular immunoglobulin-like domains for NGF binding to the Trk tyrosine kinase receptor. This step is saturable and site-specific, which is why the GO definition emphasizes binding to one or more specific sites.
Valency and receptor clustering
In simple terms: When multiple binding sites are present, receptors can be pulled together into clusters that change signaling.
Immunoglobulin divalence promotes B-cell antigen receptor cluster scale-dependent functions, showing that the number of binding sites on the ligand directly influences receptor organization and signaling output. This means that immunoglobulin receptor binding is not just a binary on/off event; it is sensitive to ligand valency and receptor density. Clustering can amplify or diversify downstream signals, which is a key reason the term is studied in immune cell activation.
Domain architecture and binding specificity
In simple terms: The shape of the receptor domains determines which immunoglobulins or ligands it can bind.
Receptor domains, especially immunoglobulin-like domains, dictate binding specificity. The polymeric immunoglobulin receptor uses such domains to bind polymeric immunoglobulins, and the Trk receptor requires its extracellular immunoglobulin-like domains for NGF binding. I-type lectins, which contain immunoglobulin-like domains, further illustrate how this fold is used across receptor families. These structural features explain why GO:0034987 annotations often cluster around receptors with immunoglobulin or immunoglobulin-like domains.
Interference and regulation by exogenous factors
In simple terms: Other molecules can get in the way and block or modify the binding event.
Immunoglobulin receptor binding can be inhibited or modulated by non-immunoglobulin components. Human milk contains both immunoglobulin and non-immunoglobulin components that inhibit Clostridium difficile toxin A-receptor binding, demonstrating that the binding interface is accessible to competing factors. Pathogen-receptor interactions, such as those of picornaviruses, also show that receptor binding is a contested step that can be targeted. These examples support the idea that GO:0034987 is a regulated and druggable interaction.
Downstream consequences of binding
In simple terms: Once binding happens, the receptor can send signals or transport cargo.
The functional outcome of immunoglobulin receptor binding depends on the receptor. Fc receptors and immunoglobulin binding factors can trigger immune cell activation or clearance, while the polymeric immunoglobulin receptor mediates transport across epithelia. In B cells, binding valency shapes cluster scale and function. Thus, GO:0034987 is the molecular entry point for diverse cellular outcomes, and separating binding from downstream effects is a common experimental goal.
Key Genes Involved in GO:0034987 immunoglobulin receptor binding
The following genes and proteins are representative actors in immunoglobulin receptor binding, based on the verified literature and their receptor or ligand roles.
| Gene | Major Role | Research Relevance |
|---|---|---|
| FCGR1A | High-affinity Fc gamma receptor that binds immunoglobulin G | Model for Fc receptor binding and immune complex recognition |
| FCGR2A | Low-affinity Fc gamma receptor involved in immune cell activation | Target for studying binding affinity and signaling |
| FCGR3A | Fc gamma receptor on NK cells and macrophages | Relevant to antibody-dependent cellular cytotoxicity |
| FCER1A | High-affinity IgE receptor subunit | Model for immunoglobulin receptor binding in allergy |
| PIGR | Polymeric immunoglobulin receptor that binds polymeric IgA and IgM | Studied in mucosal immunity and transcytosis |
| BCR | B-cell antigen receptor complex that binds antigen and immunoglobulin | Central to B-cell clustering and activation |
| NGF | Ligand that requires immunoglobulin-like domains for Trk binding | Example of immunoglobulin-domain-dependent receptor binding |
| NTRK1 | Trk tyrosine kinase receptor with extracellular immunoglobulin-like domains | Model for immunoglobulin-like domain binding |
| SIGLEC1 | I-type lectin with immunoglobulin-like domains | Illustrates immunoglobulin-domain receptor families |
| SIGLEC4 | I-type lectin family member | Relevant to immunoglobulin-like domain recognition |
| CD22 | I-type lectin and B-cell receptor regulator | Links immunoglobulin-like domains to B-cell signaling |
| CD33 | I-type lectin and myeloid receptor | Model for immunoglobulin-like domain binding |
| HSPA5 | Binding immunoglobulin protein (BiP) chaperone | Studied in stress and receptor interaction contexts |
| SIGMAR1 | Sigma-1 receptor that interacts with binding immunoglobulin protein | Example of non-classical immunoglobulin-related binding |
| JCHAIN | Joining chain for polymeric immunoglobulins | Supports polymeric immunoglobulin receptor binding |
| FCAR | Fc alpha receptor for IgA | Model for immunoglobulin receptor binding |
| FCGRT | Neonatal Fc receptor that binds IgG | Key model for immunoglobulin transport and binding |
How Is immunoglobulin receptor binding Regulated?
Immunoglobulin receptor binding is regulated at multiple levels. Ligand valency and receptor density control clustering and signaling output, as shown for the B-cell antigen receptor. Receptor domain composition, especially the presence of immunoglobulin-like domains, determines whether binding can occur. Exogenous factors such as human milk components can inhibit toxin-receptor binding, indicating that the interaction can be blocked by competing molecules. In addition, chaperone and stress-related proteins such as binding immunoglobulin protein (BiP) and sigma-1 receptor can interact in ways that influence receptor-related binding events. Together, these mechanisms show that GO:0034987 is not a static property but a regulated interaction.
immunoglobulin receptor binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PIGR | Mucosal immunity and immunoglobulin transport defects | Knockout epithelial cell lines and transport assays |
| FCGR3A | Antibody-dependent cellular cytotoxicity in infection and cancer | Point-mutation knock-in of receptor variants |
| BCR | B-cell activation and autoimmunity | Valency-controlled B-cell receptor clustering models |
| NTRK1 | Neurotrophic signaling and receptor tyrosine kinase biology | Domain-deletion knock-in to test immunoglobulin-like domain requirement |
| HSPA5 | Stress-related receptor interaction and chaperone biology | Knockout and overexpression in stress models |
Infectious disease and toxin-receptor interference
Immunoglobulin receptor binding is directly relevant to infectious disease because pathogens and toxins can exploit or block receptor interactions. Human milk components, including immunoglobulin and non-immunoglobulin fractions, inhibit Clostridium difficile toxin A-receptor binding, showing that the binding interface can be protected by host factors. Picornavirus-receptor interactions further demonstrate that receptor binding is a critical step in viral entry. These examples make GO:0034987 a target for anti-infective strategies that aim to block pathogen-receptor engagement.
Immune dysregulation and B-cell biology
Altered immunoglobulin receptor binding can affect B-cell activation and immune complex recognition. Immunoglobulin divalence promotes B-cell antigen receptor cluster scale-dependent functions, linking binding valency to signaling outcomes. Fc receptors and immunoglobulin binding factors are central to immune cell activation and clearance, and their dysfunction can contribute to autoimmunity or immunodeficiency. Thus, studying GO:0034987 helps explain how immune responses are tuned by receptor-ligand interactions.
Mucosal immunity and transport defects
The polymeric immunoglobulin receptor binds polymeric IgA and IgM and mediates their transport across epithelia. Defects in this binding or transport can compromise mucosal immunity, making PIGR and its ligands important for studies of mucosal defense. This connects GO:0034987 to diseases of barrier surfaces and to vaccine strategies that aim to induce mucosal antibodies.
Neurotrophin receptor binding and neurological models
NGF binding to the Trk tyrosine kinase receptor requires the extracellular immunoglobulin-like domains, showing that immunoglobulin-like folds can mediate neurotrophic signaling. This expands the relevance of GO:0034987 beyond classical immunology into neurobiology and receptor tyrosine kinase biology. Experimental models that disrupt these domains can help dissect binding versus signaling.
From immunoglobulin receptor binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does the receptor bind immunoglobulin directly? | Knockout of the receptor gene followed by binding assays |
| Which receptor domain is required for binding? | Point mutations in immunoglobulin-like domains |
| Does valency change receptor clustering? | Knock-in of dimeric versus monomeric ligand variants |
| Can a competitor block receptor binding? | Overexpression of competitor or inhibitor proteins |
| Is binding sufficient for downstream signaling? | Tagged knock-in receptor for imaging and signaling readouts |
| Does loss of binding alter mucosal transport? | Knockout of PIGR in epithelial cells |
How to Study the immunoglobulin receptor binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Surface plasmon resonance | Binding affinity and kinetics | Receptor-ligand interaction studies |
| Flow cytometry | Cell-surface binding and receptor density | Immunoglobulin binding to live cells |
| ELISA | Competitive or direct binding | Screening for inhibitors of receptor binding |
| CRISPR knockout | Loss of binding after gene disruption | Testing receptor requirement |
| Point-mutation knock-in | Role of specific receptor residues | Domain mapping of binding sites |
| Super-resolution imaging | Receptor clustering and spatial organization | Valency-dependent clustering studies |
| Proteomics | Associated proteins and complexes | Discovery of co-receptors and chaperones |
Binding assays and surface plasmon resonance
Direct binding between immunoglobulins and their receptors can be measured using surface plasmon resonance, ELISA, or flow cytometry-based binding assays. These methods quantify affinity, avidity, and the effect of valency, which is critical for understanding GO:0034987. They are typically applied to purified receptor ectodomains or to cells expressing wild-type and mutant receptors.
CRISPR-based genetic perturbation
CRISPR knockout, point mutation, and knock-in models allow researchers to test whether a specific receptor domain or residue is required for immunoglobulin receptor binding. By comparing binding in wild-type and mutant cells, the causal contribution of the receptor to the interaction can be established. These approaches are especially useful for separating binding from downstream signaling.
Imaging and clustering analysis
Advanced imaging can visualize receptor clustering at the cell surface after immunoglobulin binding. Immunoglobulin divalence promotes B-cell antigen receptor cluster scale-dependent functions, which can be monitored by super-resolution or single-molecule imaging. Tagged knock-in receptors enable tracking of binding-induced reorganization in live cells.
Proteomics and interactomics
Proteomic approaches can identify proteins that associate with immunoglobulin receptors before or after binding. This is useful for discovering co-receptors, chaperones, and signaling partners, as illustrated by interactions involving binding immunoglobulin protein and sigma-1 receptor. Interactomics can also reveal how competitor molecules interfere with receptor binding.
How CRISPR Can Be Used to Study GO:0034987 immunoglobulin receptor binding
Knockout
CRISPR knockout of immunoglobulin receptor genes is used to eliminate binding and determine whether the receptor is necessary for a given response. For example, knocking out PIGR can test its role in polymeric immunoglobulin transport. Knockout models are also useful for validating antibody specificity in binding assays.
Point Mutation
Point mutations in immunoglobulin-like domains can disrupt binding without removing the entire receptor, allowing precise mapping of the interaction interface. This is particularly valuable for receptors such as NTRK1, where extracellular immunoglobulin-like domains are required for NGF binding. Point-mutation models help distinguish binding defects from folding or trafficking defects.
Knock-in
Knock-in of tagged or variant receptors enables visualization and functional testing of immunoglobulin receptor binding in native contexts. Tagged knock-in receptors can be used to monitor clustering after ligand binding. Knock-in of disease-associated variants can also reveal how binding affinity changes contribute to immune dysregulation.
Overexpression
Overexpression of receptors or competing ligands can enhance or inhibit immunoglobulin receptor binding, depending on the experimental design. This approach is useful for testing whether increasing receptor density promotes clustering and signaling. Overexpression of competitor proteins can also mimic the inhibitory effects seen with human milk components on toxin-receptor binding.
How EDITGENE Supports immunoglobulin receptor binding Research
Researchers studying immunoglobulin receptor binding-related genes often need to determine whether a candidate gene is causally involved in receptor engagement, signaling, or transport. EDITGENE provides CRISPR-based cell models and screening services that allow precise interrogation of GO:0034987 in relevant cell types.
Contact EDITGENE today to design your custom CRISPR model for immunoglobulin receptor binding research.
Frequently Asked Questions About immunoglobulin receptor binding
What is GO:0034987?
GO:0034987 is the Gene Ontology molecular function term for immunoglobulin receptor binding, defined as binding to one or more specific sites on an immunoglobulin receptor molecule.
What is another name for immunoglobulin receptor binding?
The synonym is Fc receptor binding, though the term also covers polymeric immunoglobulin receptors and other immunoglobulin-like receptors.
What genes are involved in immunoglobulin receptor binding?
Representative genes include FCGR1A, FCGR2A, FCGR3A, FCER1A, PIGR, BCR, NTRK1, and SIGLEC family members.
How does immunoglobulin valency affect receptor binding?
Immunoglobulin divalence promotes B-cell antigen receptor cluster scale-dependent functions, meaning valency influences receptor clustering and signaling.
Can pathogens block immunoglobulin receptor binding?
Yes, human milk components including immunoglobulin and non-immunoglobulin fractions inhibit Clostridium difficile toxin A-receptor binding.
What domains are required for immunoglobulin receptor binding?
Immunoglobulin-like domains are often required, as shown for NGF binding to the Trk tyrosine kinase receptor and for polymeric immunoglobulin receptor function.
How can I study immunoglobulin receptor binding with CRISPR?
CRISPR knockout, point mutation, knock-in, and overexpression models can test receptor requirement, domain function, clustering, and competition.
Is immunoglobulin receptor binding relevant to mucosal immunity?
Yes, the polymeric immunoglobulin receptor binds polymeric IgA and IgM and mediates transport across epithelia.
What diseases are linked to immunoglobulin receptor binding?
It is linked to infectious disease, immune dysregulation, mucosal transport defects, and neurotrophic signaling disorders.
What methods measure immunoglobulin receptor binding?
Surface plasmon resonance, flow cytometry, ELISA, imaging, and proteomics are commonly used.
Conclusion
GO:0034987 immunoglobulin receptor binding is a focused molecular function that captures the direct physical engagement of immunoglobulins or immunoglobulin-like ligands with their receptors. It is central to immune signaling, mucosal transport, pathogen-receptor interactions, and neurotrophic receptor biology. Because the binding step is often the first committed event, it is a high-value target for therapeutic and diagnostic development. CRISPR-based models and binding assays provide the tools needed to dissect this function with precision.
References
- 1. Dai LA et al.. 2022. Sigma-1 Receptor and Binding Immunoglobulin Protein Interact with Ulinastatin Contributing to a Protective Effect in Rat Cerebral Ischemia/Reperfusion.. World Neurosurg 158:e488-e494 PMID: 34767993
- 2. Yang S et al.. 2021. Molecular cloning and binding analysis of polymeric immunoglobulin receptor in largemouth bass (Micropterus salmoides).. Mol Immunol 133:14-22 PMID: 33610122
- 3. Yilmaz E et al.. 2025. Immunoglobulin divalence promotes B-cell antigen receptor cluster scale-dependent functions.. Cell Mol Immunol 22(9):1093-1108 PMID: 40770085
- 4. Rossmann MG et al.. 2002. Picornavirus-receptor interactions.. Trends Microbiol 10(7):324-31 PMID: 12110211
- 5. Angata T et al.. 2002. I-type lectins.. Biochim Biophys Acta 1572(2-3):294-316 PMID: 12223277
- 6. Fridman WH. 1991. Fc receptors and immunoglobulin binding factors.. FASEB J 5(12):2684-90 PMID: 1916092
- 7. Rolfe RD et al.. 1995. Immunoglobulin and non-immunoglobulin components of human milk inhibit Clostridium difficile toxin A-receptor binding.. J Med Microbiol 42(1):10-9 PMID: 7739018
- 8. Pérez P et al.. 1995. NGF binding to the trk tyrosine kinase receptor requires the extracellular immunoglobulin-like domains.. Mol Cell Neurosci 6(2):97-105 PMID: 7551570
